Schechter Investment Advisors LLC Decreases Stake in Zoetis Inc. (NYSE:ZTS)

Schechter Investment Advisors LLC cut its position in Zoetis Inc. (NYSE:ZTS - Free Report) by 17.4% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 10,896 shares of the company's stock after selling 2,290 shares during the quarter. Schechter Investment Advisors LLC's holdings in Zoetis were worth $1,794,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of ZTS. Brighton Jones LLC raised its position in shares of Zoetis by 180.4% during the fourth quarter. Brighton Jones LLC now owns 4,629 shares of the company's stock worth $754,000 after acquiring an additional 2,978 shares during the last quarter. Bank Pictet & Cie Europe AG increased its holdings in Zoetis by 5.4% in the fourth quarter. Bank Pictet & Cie Europe AG now owns 419,530 shares of the company's stock worth $68,354,000 after purchasing an additional 21,470 shares in the last quarter. Proficio Capital Partners LLC increased its holdings in Zoetis by 61.0% in the fourth quarter. Proficio Capital Partners LLC now owns 3,053 shares of the company's stock worth $497,000 after purchasing an additional 1,157 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. bought a new stake in Zoetis in the fourth quarter worth approximately $8,710,000. Finally, Intact Investment Management Inc. bought a new stake in Zoetis in the fourth quarter worth approximately $65,000. 92.80% of the stock is currently owned by institutional investors.

Insider Activity at Zoetis

In related news, EVP Roxanne Lagano sold 652 shares of Zoetis stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $170.00, for a total value of $110,840.00. Following the completion of the sale, the executive vice president owned 15,129 shares of the company's stock, valued at $2,571,930. The trade was a 4.13% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.18% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of equities research analysts have commented on ZTS shares. Stifel Nicolaus cut Zoetis from a "buy" rating to a "hold" rating and reduced their price objective for the company from $165.00 to $160.00 in a research note on Wednesday, June 18th. Leerink Partners cut Zoetis from an "outperform" rating to a "market perform" rating and reduced their price objective for the company from $180.00 to $155.00 in a research note on Thursday. Piper Sandler raised their price objective on Zoetis from $205.00 to $210.00 and gave the company an "overweight" rating in a research note on Monday, May 12th. Finally, UBS Group reduced their price objective on Zoetis from $189.00 to $170.00 and set a "neutral" rating for the company in a research note on Wednesday, May 7th. Three equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Zoetis has an average rating of "Moderate Buy" and an average target price of $204.63.

Zoetis Stock Down 1.0%

NYSE:ZTS traded down $1.54 during trading hours on Thursday, reaching $150.00. 3,575,244 shares of the company traded hands, compared to its average volume of 2,610,616. The business's 50-day moving average price is $161.00 and its two-hundred day moving average price is $161.54. The stock has a market capitalization of $66.78 billion, a P/E ratio of 26.93, a P/E/G ratio of 2.51 and a beta of 0.91. Zoetis Inc. has a 1 year low of $139.70 and a 1 year high of $200.33. The company has a current ratio of 1.74, a quick ratio of 1.04 and a debt-to-equity ratio of 1.12.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported $1.48 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.40 by $0.08. The business had revenue of $2.22 billion during the quarter, compared to analysts' expectations of $2.20 billion. Zoetis had a return on equity of 55.48% and a net margin of 27.12%. The firm's quarterly revenue was up 1.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.38 earnings per share. Analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Friday, July 18th will be issued a $0.50 dividend. This represents a $2.00 annualized dividend and a dividend yield of 1.33%. The ex-dividend date is Friday, July 18th. Zoetis's payout ratio is currently 35.91%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.